Edition:
United States

Intec Pharma Ltd (NTEC.OQ)

NTEC.OQ on NASDAQ Stock Exchange Capital Market

5.30USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.30
Open
$5.30
Day's High
$5.45
Day's Low
$5.15
Volume
23,726
Avg. Vol
24,044
52-wk High
$9.80
52-wk Low
$4.20

Summary

Name Age Since Current Position

John Kozarich

67 2016 Chairman of the Board

Jeffrey Meckler

50 2017 Chief Executive Officer, Vice Chairman of the Board

Nir Sassi

41 2016 Chief Financial Officer

Nadav Navon

48 2017 Chief Operating Officer

Walt Linscott

57 2017 Chief Administrative Officer

Liat Flaishon

48 2014 Vice President-Clinical and Business Development

Biographies

Name Description

John Kozarich

Dr. John W. Kozarich has been appointed Chairman of the Board at Intec Pharma Ltd effective May 16, 2016. Dr. Kozarich has nearly 40 years of experience in the biopharmaceutical industry and academia. His work experience includes the following roles: Chairman of Ligand Pharmaceuticals, Chairman and President of ActivX Biosciences, Vice President at Merck Research Laboratories. Dr. Kozarich was named Director of the Year for Companies in Transition by the Corporate Directors Forum for his work at Ligand and ActivX. He holds a Bachelor of Science degree in Chemistry Boston College and a Doctorate of Science degree in Biological Chemistry from the Massachusetts Institute of Technology. In addition, Dr. Kozarich was an NIH Postdoctoral Fellow at Harvard University.

Jeffrey Meckler

Mr. Jeffrey A. Meckler has been appointed Chief Executive Officer at Intec Pharma Ltd effective July 10, 2017, in addition to his role of Vice Chairman of the Board at the Company, which he holds since April 9, 2017. His work experience includes the following roles: Chief Executive Officer at Cocrystal Pharma, Inc., Director at QLT Inc, Director at Retrophin, Inc and has worked at Pfizer for 17 years where he held leadership positions in corporate strategic planning, acquisitions and business development, market research, manufacturing systems and sales operations analysis. He holds a Bachelor of Science degree in Industrial Management and a Master of Science degree in Industrial Administration, both from Carnegie Mellon University and a Juris Doctor degree from Fordham University School of Law.

Nir Sassi

Mr. Nir Sassi has been appointed Chief Financial Officer at Intec Pharma Ltd effective August 1, 2016. Until this date, he will continue to hold the Vice President - Finance role at the Company. He holds a Bachelors degree in Accounting and Economics from Ben Gurion University. He is a Certified Chartered Accountant.

Nadav Navon

Dr. Nadav Navon has been appointed Chief Operating Officer at Intec Pharma Ltd effective July 27, 2017. His work experience includes the following roles: Executive Vice President-Research & Development and Operations at the Company (from March 31, 2015), Vice President of Research & Development and Operations at the Company (from May 2013), Head of analytical and quality assurance operations at Sharon Laboratories Ltd (2001-2006) and Leader of a number of research and development projects at the Negev’s Nuclear Research Center. Dr. Navon holds a Bachelor of Science degree in Chemistry, a Doctorate of Science degree in Inorganic and Analytical Chemistry and a MBA degree, all from Ben Gurion University.

Walt Linscott

Mr. Walt Addison Linscott has been appointed Chief Administrative Officer at Intec Pharma Ltd effective October 26, 2017. His work experience includes the following roles: Lawyer, Co-Founder of a strategic Consulting Entity, General Counsel and Secretary at Cocrystal Pharma, Inc (until March 2017), Global Strategic Legal Advisor for Thompson Hine, LLP and General Counsel and Corporate Secretary at Carestream Health, Inc (January 2011-December 2014). He holds a Bachelors degree from Syracuse University and a Juris Doctor degree from University of Dayton.

Liat Flaishon

Dr. Liat Flaishon has been appointed Vice President-Clinical and Business Development at Intec Pharma Ltd. effective March 24, 2014. Dr. Flaishon holds a Doctorate of Medicine degree in Immunology from the Weizmann Institute of Science and a Doctorate of Medicine degree from Tel Aviv University. Dr. Flaishon's previous work experience includes a Business Development Director role at Pluristem Therapeutics Inc, between 2012 and 2013, and a Director role at Teva-Pharmaceutical Industries Ltd. between 2007 and 2012.

Basic Compensation

Options Compensation